Local Concentrators for Protein Crystallization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional crystallization systems face challenges in achieving efficient nucleation of proteins at low concentrations and require high supersaturated conditions, leading to prolonged crystallization times and potential denaturation, which limits the scalability and cost-effectiveness of protein-based drug manufacturing.
Innovation Solution
The use of local concentrators, such as nanoparticles functionalized with specific binding agents, that interact with proteins to increase local protein concentration and facilitate nucleation at lower concentrations by acting as heterogeneous nucleation sites, allowing for faster crystallization and control over crystal characteristics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional crystallization systems are used to achieve efficient nucleation of proteins, then high supersaturated conditions are required, but this leads to prolonged crystallization times and potential denaturation
Solution Approach 1:
The patent introduces local concentrators (nanoparticles or surfaces with binding agents) as intermediary structures that mediate between the protein solution and the crystallization process. These local concentrators bind proteins selectively to create high local concentration zones, enabling efficient nucleation without requiring high bulk supersaturation conditions, thus reducing crystallization time and preventing denaturation
Solution Approach 2:
The patent applies local quality by creating localized regions of high protein concentration at the surface of particles or binding agents, while the bulk solution remains at lower concentration. This spatial differentiation allows nucleation to occur efficiently at specific locations without subjecting the entire system to harsh supersaturated conditions that cause denaturation and prolong processing time
2Reliability
If high supersaturated conditions are used to achieve efficient nucleation, then crystallization can proceed, but protein denaturation occurs
Solution Approach 1:
The patent creates localized high-concentration zones at particle surfaces or binding agent interfaces where nucleation occurs, while the bulk solution maintains lower protein concentrations. This spatial differentiation enables efficient nucleation at specific locations without exposing the entire protein population to denaturing supersaturated conditions
Solution Approach 2:
Local concentrators act as intermediary structures that facilitate nucleation through controlled protein accumulation at their surfaces. These intermediaries provide a gentle concentration mechanism that avoids the harsh conditions causing denaturation, allowing reliable nucleation under milder bulk solution conditions
3Reliability
If conventional crystallization methods are used, then the process can be completed, but scalability and cost-effectiveness are limited
Solution Approach 1:
The local concentrators are designed to autonomously perform protein concentration and nucleation initiation through their binding properties. This self-service capability eliminates the need for complex external control mechanisms and harsh condition adjustments, enabling scalable implementation across different production volumes without proportionally increasing cost or complexity
Solution Approach 2:
The patent fundamentally changes the concentration parameter distribution from uniform bulk supersaturation to localized high concentration at particle surfaces. This parameter transformation enables crystallization to proceed under milder bulk conditions, improving protein stability and allowing the process to be scaled up for manufacturing without the limitations of conventional methods
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly increases the nucleation rate and enables crystallization in undersaturated conditions, reducing the time and cost associated with protein-based drug manufacturing by allowing for high-concentration sub-cutaneous delivery and improving the stability and shelf life of crystalline products.
Implementation Method 1
a plurality of selective binding agents bound to an external surface of the particle, wherein the areal density of the selective binding agents over the external surface of the particles is less than or equal to 100 per nm2
Implementation Method 2
crystalline material or a precursor thereof in contact with at least one of the selective binding agents
Implementation Method 3
generating a crystal comprising the solubilized crystal precursor
Data Source
AI summary
Crystal nucleation, and associated articles, systems, and methods, are generally described.